India: Treat For Tennis Fans – Sharapova Ban Reduced

Last Updated: 7 October 2016
Article by Alishan Naqvee and Dhruv Manchanda

The Court of Arbitration for Sports ("CAS") has finally given its arbitral award ("CAS Award") in the dispute between Ms. Maria Sharapova and the International Tennis Federation ("ITF") wherein Sharapova had challenged the 2 year ban imposed by the Independent Tribunal appointed by the ITF ("Tribunal") in its decision dated June 6, 2016 (Decision) (which has been analysed in detail in our earlier article circulated on July 4, 2016, also available at The ban was imposed on Sharapova for committing an anti-doping rule violation under article 2.1 of the Tennis Anti-Doping Programme 2016 ("TADP").

Brief Facts and Arguments Presented in front of CAS Panel:

During the proceedings before the CAS, Sharapova after summarizing her personal and sporting history, underlined that she has throughout her career, maintained an immaculate disciplinary record and would never deliberately use prohibited substances and be in violation of the anti-doping rules. During her submissions, Sharapova while referring to the provisions of TADP prescribing consequences for violation of anti-doping rules, primarily referred to Article 10.5 of TADP which allows for a reduction in the penalty on the basis of the principle "No Significance Fault or Negligence". As per the CAS Award, during the proceedings, Sharapova, inter alia:

  • accepted that she bears some degree of fault and therefore does not plead a defence of "No Fault or Negligence";
  • agreed to disqualification of her results at the 2016 Australian Open and did not challenge the Decision in this regard;
  • confirmed that the lack of intentionality (in committing the violation for purposes of article 10.2.2 of the TADP) was acknowledged by the Tribunal and therefore the sanction should be 2 years of ineligibility;
  • emphasized that CAS has discretion to reduce the period of ineligibility to 1 year upon establishment of the principle "No Significant Fault or Negligence"; and
  • requested the CAS panel to exercise its discretion to reduce the ineligibility to a shorter period, consistent with the principle of proportionality.

Sharapova further described the extent and effectiveness of the system she had in place to ensure anti-doping compliance and underlined that "athletes are permitted to delegate elements of their anti-doping obligations. If a mistake later arises, the fault to be assessed is not that made by the delegate but the fault made by the athlete in his/her choice".

In light of the above statement, it was deliberated that "Sharapova cannot be faulted for relying on the services of one of the largest best resourced sports managements firms and of Mr Eisenbud, who had advised her since she was 11 years old, had performed thorough anti-doping checks and assistance for her over several years with diligence and urgency, and understood better than anybody the catastrophic consequences of a positive test."

Sharapova argued that the World Anti-Doping Agency ("WADA") was aware that Meldonium was widely known under the name of 'Mildronate' and a large number of athletes use 'Mildronate' but still failed to mention the name 'Mildronate' on the 2016 Prohibited List and to issue specific warnings in this regard. Sharapova, thus, contended that her error, to an extent, is also attributable to WADA's failure and therefore, under the circumstances, she met the the criteria of "No Significant Fault or Negligence".

The ITF had submitted that "this case has exposed the failure of the Appellant to take responsibility for discharging her anti-doping responsibilities herself (in particular, checking whether her medication contained any prohibited substances). Instead [she] delegated the job to her (hopelessly unqualified) manager, without giving him any proper instructions or procedures, or doing anything to supervise or control his work or to check that what he had done was sufficient to ensure she would not fall foul of the anti-doping rules. In such circumstances, it was hardly surprising that this arrangement failed completely, causing her to test positive in January 2016 for a drug, meldonium, that she had been taking for a long time but that had just been put onto the Prohibited List. In such circumstances, the rules and the constant CAS jurisprudence are clear: against the starting-point that she must use 'utmost caution' to ensure that no prohibited substance enters her system, the Appellant's failure to delegate her responsibilities to a properly qualified person, to provide proper instructions, to lay down proper procedures, and to supervise that person's compliance with those procedures, make her significantly negligent, and therefore the Independent Tribunal "was right not to give her any reduction from the two-year ban proscribed in the Code and the TADP".

After hearing both the parties, following issues were to be examined and decided upon by the CAS panel:

  1. What is the player's level of fault and more specifically, did the player commit the anti-doping rule violation with "No Significance Fault or Negligence"?
  2. If so, what is the proper sanction for period of ineligibility for the player?

Looking into the facts of the case and hearing both the parties, the CAS panel opined that:

  • Sharapova chose to rely on Mr. Eisenbud and his organization for performance of all anti-doping related matters, which choice was found to be reasonable by CAS panel. However, Sharapova did not establish any procedure to supervise and control the actions performed by Mr. Eisenbud while discharging the task he was entrusted to perform nor was there any procedure for reporting or verification to ensure actual discharge of duties by Mr. Eisenbud; and
  • Sharapova had reduced perception of the risk being incurred while using 'Mildronate' due to number of reasons which, inter alia, included that 'Mildronate' was initially consumed by Sharapova under the supervision and prescription of Dr. Skalny (post verification of the substance from ITF) and the same was consumed for medical reasons and not as a performance enhancing drug.

Final Award:

Sharapova's claim to the principle of "No Significant Fault or Negligence" was accepted by CAS panel. For the purposes of period of ineligibility, the CAS panel noted that Sharapova does bear some degree of fault which prevents reduction of the period of ineligibility to the minimum prescribed period under the TADP. CAS panel thus decided that an ineligibility period of 15 months is appropriate to the degree of fault attributable to Sharapova.

Effects of the Award:

Post the CAS Award, Sharapova has made a public statement claiming that October 4, 2016 has been one of her happiest days and is planning a strong return to the tennis circuit in 2017.

2016 has arguably been one of the historic years in women tennis, during which the game saw two new first time grand slam champions [Angelique Kerber winning the Australian Open and US Open (eventually gaining number 1 rank) and Garbine Muguruza winning the French Open] and Monica Puig winning the Olympic gold medal.

Sharapova, having won all 4 grand slams at least once, and settling for silver at the London Olympics in 2012, would have been eagerly looking forward to lay her hands on gold in Rio Olympics in 2016. Thus, the ban imposed on Sharapova definitely was a great setback for Sharapova in her tennis career and came possibly at the most dreaded time, as it took away the opportunity of participating in Rio Olympics.

However, the CAS Award has come as a big relief and the reduced period of ineligibility 15 months is deemed to be commencing from January 26, 2016 till midnight of April 25, 2017. This effectively means that Sharapova will be missing out on the hard court season of tennis tournaments in beginning of 2017 and her first tennis tournament will be the clay court tournament beginning the week of May 1, 2017 in Prague, Czech Republic or in Rabat, Morocco.

This also means that for second consecutive year Sharapova will be missing out on the opportunity of participating in the Stuttgart Open by 2 days as the tournament is scheduled for the week of April 24, 2017. Stuttgart Open and has arguably been one of Sharapova's most preferred clay court tournaments where she won for 3 (three) consecutive years from 2012 to 2014.

At the time of her return, Sharapova will have no ranking points and will be dependent on wild cards for her comeback tournaments as she has not had a chance of defending her ranking points for any of the tournaments in 2016. Sharapova will have a chance of participating in maximum 4 tournaments to play some competitive tennis, gain her form back and also gain some ranking points before the French Open, 2017 (scheduled to commence on May 29, 2017). The women singles draw of the French Open, 2017 will be an interesting proposition as Sharapova will most likely be going into the draw as an unseeded player. Sharapova, in all probabilities, would be looking to climb the rankings as early as possible and go into Wimbledon (being one of her favourite tournaments) as a seeded player. Sharapova on the centre court would be a sight for sore eyes, for she was missing in action at the 2016 Wimbledon Championships.

Another noteworthy proposition is that the timing of Sharapova's return to professional tennis is the beginning of the clay court season which is not the most preferred surface for Sharapova, even though during her career she has won 12 clay court tournaments which includes French Open in 2012 and 2014.

Sharapova's return in May, 2017 will be eagerly awaited by the tennis fraternity and fans across the globe. The 15-month break from tennis although quite stressful from the player's perspective, may prove to be a blessing in disguise for Sharapova, as the rest for her muscles and body during this period may eventually help her prolong her tennis career. Sharapova will definitely be looking for a strong comeback and go on to add some more trophies to her cabinet and will also be looking at strengthening her chances of participating in the 2020 Tokyo Olympics and claiming an Olympic gold medal to add to her already accomplished tennis achievements.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Alishan Naqvee
Dhruv Manchanda
In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions